Tag Archives: FirstWord Pharma

Biogen spinoff Bioverativ buys Bristol-Myers’ iPierian spinout True North for $825 million; deal shows how to get several bites at the same assets






The News: Bioverativ Inc. (Waltham MA) announced that it entered into a definitive agreement to acquire True North Therapeutics Inc. (South San Francisco) for up to $825 million, including an… Read more »

Abbvie’s biosimilar fight over Humira patent highlights differences between EU and US regulatory mindsets






The News: Coherus BioSciences Inc. (Redwood City CA) last week announced that the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office ruled in the company’s… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?






The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

GOP healthcare bill heads to Senate where fate far from certain






The News: The US House of Representatives on Thursday (May 4, 2017) voted 217 to 213 in favor of proposed legislation that would repeal and replace parts of the Affordable Care Act (ACA), signed into… Read more »

Wall Street cheers as Axovant snags biotech star David Hung; failed Alzheimer’s drug not impressed






The News: Axovant Sciences Ltd. (Hamilton Bermuda) announced that former Medivation Inc. (San Francisco) chief executive and founder David Hung has been selected as its next CEO effective April 7, 2017 sending… Read more »

Musk’s new AI startup aims at human brain; tech giants already in that space






Entrepreneur Elon Musk has confirmed on via Twitter the launch of a new venture company, called Neuralink, which aims to develop a brain-computer interface. According to people familiar with the matter, the company will pursue what… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed






Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

German Merck, flying under Street’s radar, gets no respect; but not for long






Steve’s Take: Wall Street analysts are perhaps familiar with the history behind the two Pharma powerhouses, US-based Merck & Co., and Germany-based Merck KgaA. Until recently, however, I only had… Read more »

IPO Alert: Actelion founders launch startup on $1.5 billion J&J payday: call your broker, soon






Steve’s Take: If ever there was a “story” biotech IPO worth grabbing even a tiny piece of, this is it. First, the story: Two decades ago Jean-Paul and Martine Clozel… Read more »

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?






The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »